Avalon Trust Co Buys Shares of 35,466 Thermo Fisher Scientific Inc. $TMO

Key Points

• Avalon Trust Co. purchased 35,466 shares of Thermo Fisher Scientific in the second quarter, valued at approximately $17.8 million and representing 1.1% of its portfolio. Institutional investors collectively own 89.23% of TMO.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $619.41. Recent targets range from $580 to $650.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in adjusted EPS and $11.99 billion in revenue, with revenue rising 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share.

Avalon Trust Co purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 35,466 shares of the medical research company's stock, valued at approximately $17,781,000. Thermo Fisher Scientific comprises 1.1% of Avalon Trust Co's portfolio, making the stock its 27th biggest holding.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TMO. North Dakota State Investment Board bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $7,505,000. Boston Trust Walden Corp lifted its holdings in Thermo Fisher Scientific by 9.7% in the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company's stock worth $25,480,000 after purchasing an additional 3,873 shares during the last quarter. Hudson Value Partners LLC boosted its position in Thermo Fisher Scientific by 24.9% during the second quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company's stock worth $8,349,000 after purchasing an additional 3,317 shares during the period. Xponance LLC grew its holdings in Thermo Fisher Scientific by 8.1% during the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company's stock valued at $34,358,000 after purchasing an additional 4,436 shares during the last quarter. Finally, Annex Advisory Services LLC raised its position in shares of Thermo Fisher Scientific by 12.6% in the second quarter. Annex Advisory Services LLC now owns 24,656 shares of the medical research company's stock valued at $12,361,000 after purchasing an additional 2,756 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 5,850 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company's stock, valued at approximately $8,574,720. This represents a 28.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer directly owned 24,651 shares of the company's stock, valued at approximately $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock valued at $30,643,589 over the last 90 days. Company insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on TMO. Royal Bank Of Canada lifted their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a report on Friday, July 24th. Barclays raised their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research report on Friday, April 24th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 target price on the stock. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $586.62 on Tuesday. The business's 50 day moving average is $531.72 and its 200-day moving average is $508.48. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $216.90 billion, a PE ratio of 31.56, a PEG ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. During the same period last year, the business earned $4.28 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source